Chief Executive Officer
Chairman of the Board of Directors
World Class Team
Mr. Camaisa is the current Chief Executive Officer (CEO) of Calidi Biotherapeutics and oversees execution of the Calidi Biotherapeutics business and financial operations. Calidi Biotherapeutics mission is to eradicate difficult to treat cancers. Calidi Biotherapeutics patented technology enables patients to undergo treatment with none of the well-known debilitating side effects associated with traditional cancer treatments such as hair loss, appetite loss, weight loss, nausea, harm to healthy living tissue and other detrimental health concerns. The Calidi Biotherapeutics approach leverages a patient’s own cells, bundled with a proprietary anti-cancer payload which is then targeted directly at tumorous cells while sparing the patient’s healthy cells to allow the patient’s immune system to fight and ultimately kill the cancer cells.
Previously Mr. Camaisa was the CEO and Chairman of Parallel6, Inc., whose digital mobile software platform engaged clinical trial participants, and powered the enrollment, engagement, management, and retention of those participants on behalf of pharmaceutical organizations. Parallel6 was sold to PRA Health Sciences (NASDAQ:PRAH) in Q2 of 2017. Mr. Camaisa was also instrumental in providing the company’s Series A funding. Some of their clients included, Sanofi, STSI/Genentech, Thermal Fisher, Johnson & Johnson/Janssen, Abbott/Abbvie, PPD, PRA Health, Pfizer, Roche, and the NIH, among others.
Mr. Camaisa previously founded AnakamTM, Inc., a software security company, also focused on healthcare, which safeguarded medical records online through a platform delivering NIST Level 3 multifactor authentication and security. Anakam sold over 5 million licenses to the Veterans Administration (VA) for deployment across 250 global locations, to the Center for Medicare and Medicaid, to the Department of Homeland Security and to medical device companies such as Boston Scientific and EntraHealth. Anakam was recognized by INC 500 as one of the fastest growing companies in the U.S. Equifax, Inc (NYSE:EFX) subsequently acquired Anakam in 2010.
Preceding Anakam™, Mr. Camaisa’s High Technology Solutions TM (HTS), a software systems integrator with over $50 million in revenues which was recognized as an INC 500 company three years in a row. Mr. Camaisa led HTS from a small, two-person company to one with 500+ employees across the US. HTS was sold to Wireless Facilities, Inc., now Kratos Defense (NASDAQ:KTOS) in 2004.
Mr. Camaisa successfully raised $17 million funding in 1999 from GE Capital, Intel, Ford Motor Company, and JP Morgan Chase Hambrecht & Quist to launch an Internet company, Eye Velocity, that focused on Internet Visualization.
Mr. Camaisa owns 7 U.S. patents and has received various awards from Tech America, the U.S. Small Business Association, the Asian Business Association and Deloitte FAST 50. He has been recognized and honored with the Governor's Small Business of the Year Award, the 1998 Ernst and Young Regional Entrepreneur of the Year in the Internet and Software Category and as the SBA Small Business Person of the Year.
He is a graduate of both the United States Naval Academy and the prestigious Owners Management Program at Harvard Business School.
Mr. Camaisa enthusiastically serves as member of YPO (Young Presidents Organization) San Diego Coastal Chapter as he has on several other volunteer boards including the United Way of San Diego and Opportunity International (Micro-Enterprise Loans to the Poor).
Chief Executive Officer
Chairman of the Board of Directors
Dr. Minev has also extensive expertise in immunotherapy clinical trial designs, logistics, and regulatory issues. He has a considerable supervision & management experience in industrial and academic settings and excellent skills in biotech business development, communication, and collaboration.
Prior to joining Calidi Biotherapeutics, Dr. Minev was the Director of Immunotherapy and Translational Oncology at Genelux Corporation, where he was directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy, and nanotechnology.
Dr. Minev is also an Adjunct Professor at the Moores UCSD Cancer Center. There, he served previously as Principal Investigator and Director, Laboratory of Tumor Immunology and Immunotherapy where, for more than 15 years, his research has been focused on the discovery of new target antigens for immunotherapy of cancer and the development of optimized cancer vaccines. Prior to that, Dr. Minev worked in Dr. Steven Rosenberg's Tumor Immunology Section at the Surgery Branch of the National Cancer Institute.
Dr. Minev is an Advisory Board Member of the European Society for Translational Medicine (EUSTM). He is a member of the Scientific and Clinical Advisory Boards of several biotechnology companies and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others. He is the recipient of the European Association of Cancer Research Fellowship and the Fogarty International Fellowship.
President, Medical and Scientific Affairs
Mr. Thesing has a proven track record in building companies through strategic partnerships and building operational teams. He was influential in successfully launching and building several startup companies in Silicon Valley and San Diego, as well as startup divisions within larger companies. He is also known for his role as key contributor and deal maker in buyout transactions at four technology companies: Civica, Parametric, Anakam, and Troika.
An internet pioneer with Sun Microsystems (Verisign, Travelocity), Mr. Thesing built the OEM ecosystem at Veritas Software (Dell, HP/Compaq), and the global alliances and sales channels for Troika Networks, acquired by Qlogic. He was Vice President of Channels and OEM for Anakam, a San Diego-based software company that was sold to Equifax in October 2010. Mr. Thesing holds a degree in Business, MIS & Marketing from California Polytechnic in San Luis Obispo, California.
Senior Vice President
Corporate Development & Operations
Chief Business Officer
Chief Financial Officer